mTOR pathway inhibitors, such as everolimus, should theoretically be of benefit in breast cancer as a result of the dysregulation of this pathway demonstrated by molecular studies, although initial results have been disappointing70. The gene discussed is MTOR; the disease is breast carcinoma.